http://www.e-cmh. (Fig. 1) . Based on the results of bone marrow examination, PRCA was diagnosed for the patient. Parvovirus B19 IgM and Epstein-Barr virus VCA IgM were tested to see whether these two virus co-existed, and showed negative test results. She was treated with prednisolone (1 mg/kg), but her Hb level continued to drop, and was 4.7 g/dL on 3rd day of predinisolone treatment. She received two pints of packed red blood cells (RBC), and continued corticosteroid therapy. After transfusion, her Hb level was 7.7 g/dL, and was gradually increased, reaching 10.4 g/ dL two weeks later. Reticulocyte count was increased to 15.9%, and serum TB and LDH level were decreased to 19.4 mg/dL and 927 IU/L, respectively, at that time. Prednisolone was administered at dose of 1 mg/kg for 1 month, and then the dose was tapered over two months periods. Hb level was normalized (13.4 g/dL) in two months following steroid therapy. Her liver function was completely recovered with normal Hb level nine months after initial presentation.
DISCUSSION
Although rare, AHA is sometimes complicated by hematopoeitc abnormalities, such as AIHA, PRCA, aplastic anemia and hemophagocytic syndrome.
3-5,9,10 However, AHA complicated by both AIHA and PRCA is extremely rare and only a few cases have been reported worldwide (Table 1) . 4, 11, 12 To our knowledge, this is the fourth case that has been reported in the literatures. 4, 11, 12 PRCA is a syndrome characterized by a severe normocytic anemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. It may be present as a primary hematologic disorder or secondary to various diseases like infection including parvovirus and hepatitis virus, collagen vascular disease, leukemia, lymphoma, thymoma and solid tumors. 13 A bone marrow aspirate is usually sufficient to make the diagnosis, but a biopsy may be necessary if the bone marrow smear is not optimal. The typical bone 14 To achieve remission, treatment with corticosteroids, cyclophosphamide, cyclosporine A, antithymocyte globulin, splenectomy, and plasmapheresis can be considered. Cortisosteroids are the first choice and prednisone is given orally at a dose of 1 mg/kg/d usually given until remission is induced and can be tapered. In approximately 40% of patients, remission usually occurs within 4 weeks. 4, 13 AIHA is a rare autoimmune condition in which autoantibodies directed toward RBC antigens lead to their accelerated destruction. The diagnosis of AIHA is usually based on the identification of anti-RBC autoantibodies by means of the direct antiglobulin test, and in most cases, reticulocytosis is accompanied. 15 Corticosteroids are the cornerstone of treatment and splenectomy and rituximab are both good alternatives. In cases of severe anemia, rapid transfusion can be expected to produce beneficial results, despite potential risk of alloimmunization. 15 In our case, patient displayed both AIHA and PRCA features simultaneously. Elevated serum lactate dehydrogenase level (1,600 IU/L), positive direct Coombs test, decreased haptoglobin level (<20 mg/dL) and positive hemoglobinuria confirmed the presence of AIHA, and decreased reticulocyte and marked erythroid hypoplasia in bone marrow examination confirmed the presence of PRCA. Patient was previously healthy and had no drug history, negative serology for HBV, HCV, HIV, parvovirus and Epstein-Barr virus and had no evidence of myelodysplastic syndromes, lymphoma and leukemia in bone marrow examination. We were able to rule out hemophagocytic syndrome because the patient didn't have fever, splenomegaly and bicytopenia, and there was no hemophagocytosis in bone marrow. 16 Based on these findings, the patient was diagnosed with PRCA and AIHA, caused by AHA. Corticosteroid is usually the initial treatment choice in both PRCA and AIHA. Hence steroid therapy can be considered initially under this circumstance. The optimal dose and duration are not known in the setting of PRCA and AIHA in AHA patients due to paucity of relevant data. However, steroid may be tried as in PRCA (at a dose of 1 mg/kg/d usually given until remission is induced and tapered), and this approach seems successful in managing PRCA and AIHA in patients with AHA. Although other measures (plasmapheresis, intravenous immunoglobulin, cyclosporine A) have been attempted one case (Table 1) , while the other cases, including our case, responded well to steroid therapy.
In summary, we experienced an AHA patient complicated by both PRCA and AIHA, who was successfully treated with corticosteroids and initial transfusion. 
